NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

June 29, 2016

Potential to render cancer cells less able to cope with hypoxia.

April 26, 2016

The presence of certain bacteria in the mouth may reveal increased risk for pancreatic cancer and enable earlier, more precise treatment. This is the main finding of a study led by researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center.

April 26, 2016

Melanoma, mesothelioma are the focus of first joint studies.

April 26, 2016

New findings could lead to anti-cancer drug developments that reverse immunosuppressive environments.

April 17, 2016

The American Association for Cancer Research has announced that Dafna Bar-Sagi, PhD, senior vice president and vice dean for science and chief scientific officer at NYU Langone, has been named to its Board of Directors for a three-year term formally commencing at the AACR’s annual meeting April 16-20, 2016.

April 06, 2016

Deirdre J. Cohen, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses emerging agents for the treatment of patients with gastric cancer.

March 30, 2016

Renewing a commitment to advance its reputation in lung cancer and other thoracic malignancies, NYU Langone Medical Center has announced the appointment of physician-scientist Leena Gandhi, MD, PhD, as director of thoracic medical oncology at its Laura and Isaac Perlmutter Cancer Center.

March 17, 2016

Stacy Loeb, MD, discusses how screening tests for prostate cancer work, what their benefits are, and what urological specialists need to know in order to best utilize them.

March 15, 2016

Timothy W. Strawderman, PhD, has been named the new Executive Director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, an NCI-designated cancer center.

March 14, 2016

Internationally renowned surgeon and scientist Douglas A. Levine, MD, FACOG, FACS, whose seminal biomarker research has helped to advance early detection and treatment of ovarian cancer, will join the faculty of NYU Langone Medical Center as director of the Division of Gynecologic Oncology at its Laura and Isaac Perlmutter Cancer Center and the Department of Obstetrics and Gynecology.

February 15, 2016

Arjun V. Balar, MD, discusses the phase II data demonstrating the efficacy of atezolizumab as a single agent, its potential as part of combination regimens, and planned clinical trials looking at immunotherapy in patients with metastatic bladder cancer.

February 09, 2016

Jeffrey S. Weber, MD, PhD, discusses the role that melanoma specialists can play in educating other oncologists, immunotherapy use for BRAF-mutated patients with melanoma, and how the use of chemotherapy may evolve as immunotherapies take the forefront.

February 03, 2016

Experimental drugs that alter cell metabolism also halted tumor growth and extended survival in mice with cancers caused by a gene mutated in several types of brain tumors.

February 03, 2016

Study identifies a potential drug target for inhibiting common radiation-induced fibrosis.

February 03, 2016

New study shows blood test does better job than current standard test at tracking severity and potential spread of metastatic melanoma.

February 03, 2016

The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations.

February 03, 2016

Researchers there have discovered an inherited genetic marker that might provide clinicians with a personalized tool to gauge an individual’s survival and determine which patients require closer monitoring in the years following surgery.

February 03, 2016

NYU Langone Medical Center first in Northeast to utilize new technology allowing surgeons to destroy only suspicious prostate tissue.

January 18, 2016

The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations.

December 31, 2015

Jennifer Wu, MD, sheds light on TAS-102, as well as some emerging agents likely to play a role in the treatment of patients with colorectal cancer.